ETFs Are Buying Eli Lilly (LLY) on Nov. 11

This article first appeared on GuruFocus.

ETFs bought a net $154.5 million of Eli Lilly (LLY) on Wednesday, Nov. 11, as 49 funds added shares and 11 trimmed positions. The buying extended a three-day run of positive ETF flows into the stock. That streak followed two days of net selling, when $25.7 million and $57.0 million left on Nov. 6 and Nov. 5, respectively. Before Wednesday, net buying totaled $38.9 million on Nov. 10 and $23.3 million on Nov. 9.

For the full record of ETF and guru buying and selling in LLY, see the LLY guru trades page.

Which ETFs bought LLY on Wednesday?

The largest buyers by dollar value were SPY ($74.4 million), XLV ($66.8 million) and SPYM ($5.7 million). In all, 49 ETFs added shares and 11 cut them.

SPY accounted for the largest share of the move, adding $74.4 million of stock, followed by XLV at $66.8 million and SPYM at $5.7 million. ACWI added $4.0 million, SPYG $3.1 million and IWF $2.5 million, while JGRO and GPIX contributed $2.2 million and $1.4 million. XLV holds the largest weight in Lilly among the top funds at 16.82%, compared with 1.75% for SPY. Lilly, a Healthcare company in the Drug Manufacturers – General industry, has a market cap of $1.34 trillion.

Have ETFs been buying or selling LLY lately?

Over the last 5 reported days, ETFs were net buyers on 3 and net sellers on 2, so the recent trend is mostly buying.

What does LLY do?

Eli Lilly discovers, develops, manufactures, and markets human pharmaceutical products in a single business segment, with medicines sold in approximately 90 countries. Its cardiometabolic health franchise leads the portfolio, anchored by the incretin medicines Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea, alongside Trulicity, Jardiance, and insulins.

Lilly’s trailing-12-month revenue was $86.46 billion, up 46.3% over one year, with a gross margin of 83.6% and a net margin of 31.9%. The stock trades at a P/E of 46.89, a P/B of 33.36 and a P/S of 14.94, against a market cap of $1.34 trillion. Its GF Score is 98, and the price of $1,427.28 sits below the GF Value of $1,610.19. The dividend yield is 0.47%, and the shares have returned 33.45% year to date.